| Name | Title | Contact Details |
|---|
C4 Therapeutics is pioneering a new class of drugs. C4`s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.
New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.
Bradmer Pharmaceuticals Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Advanced Urgent Care is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.